Patents by Inventor Elizabeth Louise VAN DER KAM

Elizabeth Louise VAN DER KAM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SPIRO-COMPOUNDS AS SIP MODULATORS
    Publication number: 20200055817
    Abstract: The invention relates to heterocyclic compounds of formula (I) as SIP modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment or alleviation of diseases or disorders mediated by an SIP receptor.
    Type: Application
    Filed: November 2, 2017
    Publication date: February 20, 2020
    Inventors: Wilhelm AMBERG, Jeroen VAN BERGEIJK, Herve GENESTE, Wilfried HORNBERGER, Elizabeth Louise VAN DER KAM, Udo LANGE, Mario MEZLER, Michael OCHSE, Frank OELLIEN, Patrick WALLESER, Sean C. TURNER
  • Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use
    Patent number: 10556914
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the ?-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: February 11, 2020
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Jürgen Dinges, Achim Moeller, Michael Ochse, Martin Schmidt, Michael Schulz, Sean Turner, Elizabeth Louise Van Der Kam, Anil Vasudevan
  • SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE
    Publication number: 20190367531
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the ?-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Application
    Filed: May 10, 2019
    Publication date: December 5, 2019
    Inventors: Jürgen DINGES, Achim MOELLER, Michael OCHSE, Martin SCHMIDT, Michael SCHULZ, Sean TURNER, Elizabeth Louise VAN DER KAM, Anil VASUDEVAN
  • Substituted pyrazolopyrimidines and method of use
    Patent number: 10155770
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, L1 and G1 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the ?-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: December 18, 2018
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Ramin Faghih, Achim Moeller, Michael Ochse, Frauke Pohlki, Martin Schmidt, Kevin Sippy, Sean Turner, Elizabeth Louise Van Der Kam
  • SUBSTITUTED PYRAZOLOPYRIMIDINES AND METHOD OF USE
    Publication number: 20180105530
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, L1 and G1 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the ?-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Application
    Filed: October 25, 2017
    Publication date: April 19, 2018
    Inventors: Ramin FAGHIH, Achim MOELLER, Michael OCHSE, Frauke POHLKI, Martin SCHMIDT, Kevin SIPPY, Sean TURNER, Elizabeth Louise VAN DER KAM
  • Substituted pyrazolopyrimidines and method of use
    Patent number: 9828381
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, L1 and G1 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the ?-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: November 28, 2017
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Ramin Faghih, Achim Moeller, Michael Ochse, Frauke Pohlki, Martin Schmidt, Kevin Sippy, Sean Turner, Elizabeth Louise Van Der Kam
  • SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE
    Publication number: 20170073353
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the ?-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Application
    Filed: September 15, 2016
    Publication date: March 16, 2017
    Inventors: Jürgen DINGES, Achim MOELLER, Michael OCHSE, Martin SCHMIDT, Michael SCHULZ, Sean TURNER, Elizabeth Louise VAN DER KAM, Anil VASUDEVAN
  • SUBSTITUTED PYRAZOLOPYRIMIDINES AND METHOD OF USE
    Publication number: 20160304527
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, L1 and G1 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the ?-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Application
    Filed: April 20, 2016
    Publication date: October 20, 2016
    Inventors: Ramin FAGHIH, Achim MOELLER, Michael OCHSE, Frauke POHLKI, Martin SCHMIDT, Michael SCHULZ, Kevin SIPPY, Sean TURNER, Elizabeth Louise VAN DER KAM